EGFR

Scientific explanation

EGFR is an ERBB-family tyrosine . Ligand activation or mutation (notably NSCLC exon 19/L858R) drives and signalling.

Cancers where relevant

Lung cancer Non-small-cell lung cancer EGFR-mutant NSCLC Colorectal cancer BRAF-mutant colorectal cancer HER2-amplified colorectal cancer Glioblastoma IDH-wildtype glioma Head and neck cancers

Compounds that intersect this pathway

EGCG

Green-tea catechin with in-vitro effects on RTKs, epigenetic enzymes and redox. Clinical anticancer efficacy is not established.

Evidence in mapped cancers: In Vitro · Mechanistically Plausible

Convergence partners

Other pathways that co-occur with EGFR on mapped adjunct records: PI3K/AKT.

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.